Le 14 avril 2010
Alliance Pharma plc (AIM : APH), la société pharmaceutique de spécialités, a le plaisir d'annoncer sa participation au Master Investor Show, qui aura lieu au Business Design Centre d'Islington, Londres, le 24 avril 2010. Alliance rencontrera plus de 100 sociétés cotées lors de cet évènement, qui attire plus de 2 000 investisseurs privés à fort potentiel et professionnels de l'industrie.
Alliance, dont la cote des actions a été multipliée par 14 depuis le début 2009 et a augmenté de plus de 30 % depuis début 2010, fournira aux participants un aperçu des meilleures améliorations de rendement que la Société a réalisées au cours de ces dernières années. Directors of the Company, including John Dawson, Chief Executive Officer, and Richard Wright, Finance Director, will be present to answer questions from attendees, to discuss Alliance's strategy and to give details of the major acquisition the Company completed in February 2010.
John Dawson, Chief Executive Officer, commented: "Alliance shifted its strategy in 2007 to focus on delivering improved profitability and cash generation, and has been very successful in achieving this. In 2009 alone, sales were up 44%, normalised operating profit grew 77% and cash generation more than doubled. The Cambridge Laboratories acquisition which we completed in February 2010 is set to give us another significant boost this year."
Robert Tyson, Chief Operating Officer of t1ps.com, organisers of the Master Investor Show, said: "Now in its 8th year, Master Investor Show remains the UK's leading investment show. The high calibre of speakers and sponsors highlights why this is such a well regarded event, and with 90% of tickets booked, this looks set to be our biggest and best show ever."
The organisers have held a small number of complimentary tickets back for company shareholders or other interested parties. To apply for tickets please email firstname.lastname@example.org or telephone 020 8099 0562.
For further information:
Alliance Pharma plc
+ 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
+ 44 (0) 20 7466 5000
Mark Court / Stasa Filiplic / Jennie Spivey
Notes to editors:
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and, following the Cambridge Laboratories acquisition, owns or licenses the rights to more than 50 pharmaceutical products and continues to explore opportunities to expand the range.
Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections. Alliance's sales are mainly prescription driven. Its products are distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies with their prescription requirements.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
Ce communiqué de presse est diffusé par Hugin. L'émetteur est seul responsable du contenu de ce communiqué.